Acumen Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.33 Insider Own15.73% Shs Outstand40.47M Perf Week15.85%
Market Cap192.00M Forward P/E- EPS next Y-1.10 Insider Trans0.00% Shs Float34.13M Perf Month34.56%
Income-82.70M PEG- EPS next Q-0.26 Inst Own77.90% Short Float5.93% Perf Quarter18.45%
Sales- P/S- EPS this Y0.00% Inst Trans5.23% Short Ratio8.57 Perf Half Y-29.73%
Book/sh5.34 P/B0.89 EPS next Y-13.40% ROA-43.60% Target Price17.00 Perf Year-76.58%
Cash/sh4.68 P/C1.02 EPS next 5Y32.10% ROE-58.20% 52W Range3.02 - 20.59 Perf YTD-29.73%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-76.93% Beta-
Dividend %- Quick Ratio48.80 Sales past 5Y- Gross Margin- 52W Low57.28% ATR0.37
Employees14 Current Ratio48.80 Sales Q/Q- Oper. Margin- RSI (14)68.71 Volatility11.96% 9.53%
OptionableYes Debt/Eq0.00 EPS Q/Q67.70% Profit Margin- Rel Volume0.00 Prev Close4.75
ShortableYes LT Debt/Eq0.00 EarningsMay 16 AMC Payout- Avg Volume235.98K Price4.75
Recom1.60 SMA2021.16% SMA5027.00% SMA200-33.91% Volume0 Change0.00%
Jun-30-22Initiated H.C. Wainwright Buy $15
Jan-21-22Upgrade BofA Securities Neutral → Buy $16 → $14
Jul-26-21Initiated UBS Buy $27
Jul-26-21Initiated Stifel Buy $27
Jul-26-21Initiated Credit Suisse Outperform $26
Jul-26-21Initiated BofA Securities Neutral $20
Jun-08-22 08:00AM  
May-16-22 10:00PM  
May-11-22 05:08PM  
Apr-27-22 08:00AM  
Apr-02-22 12:00AM  
Apr-01-22 05:01PM  
Mar-28-22 04:05PM  
Mar-16-22 04:15PM  
Dec-30-21 04:16AM  
Nov-25-21 07:35AM  
Nov-15-21 08:00AM  
Nov-08-21 08:00AM  
Nov-02-21 08:00AM  
Oct-07-21 08:00AM  
Oct-01-21 06:05AM  
Aug-16-21 04:05PM  
Jul-23-21 07:13PM  
Jul-01-21 05:02PM  
Jun-30-21 10:44PM  
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OConnell Daniel JosephPresident and CEONov 30Option Exercise4.471,1184,9972,685Dec 02 04:41 PM